References
- Kievit W, Fransen J, Adang EM, den Broeder AA, Bernelot Moens HJ, Visser H, et al. Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology (Oxford) 2011;50:196-203. https://doi.org/10.1093/rheumatology/keq325
- Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010;69:522-8. https://doi.org/10.1136/ard.2009.118935
- Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004;50:372-9. https://doi.org/10.1002/art.20009
- Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007;34:706-11.
- Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha- neutralizing agent. N Engl J Med 2001;345:1098-104. https://doi.org/10.1056/NEJMoa011110
- Kwok SK, Park SH. Guidelines for prevention of tuberculosis in patients with rheumatoid arthritis treated with TNF-alpha blockers. J Korean Rheum Assoc 2007;14:105-11. https://doi.org/10.4078/jkra.2007.14.2.105
- Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7. https://doi.org/10.1002/art.11137
- Kang YA, Lee HW, Yoon HI, Cho B, Han SK, Shim YS, et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 2005;293:2756-61. https://doi.org/10.1001/jama.293.22.2756
- Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 2006;36:159-67. https://doi.org/10.1016/j.semarthrit.2006.02.001
- Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A, Cucho M, Alfaro J, Perich R, et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005;64:1360-1. https://doi.org/10.1136/ard.2004.029041
- Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, Gutierrez C, Cucho M, Alfaro J, et al. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 2008;35:776-81.
- Park H, Park CW, Kim KB, Lee MJ, Zeon SJ, Shim SC, et al. A case of peritoneal tuberculosis with Poncet's disease in a patient treated with infliximab. J Rheum Dis 2011;18:55-9. https://doi.org/10.4078/jrd.2011.18.1.55
- Kim IT, Park HB, Lee SH, Hyun YK, Kim YJ, Lee YW, et al. Tuberculous peritonitis in a patient with rheumatoid arthritis treated with infliximab. J Rheum Dis 2011;18:320-3. https://doi.org/10.4078/jrd.2011.18.4.320
- Park JH, Seo GY, Lee JS, Kim TH, Yoo DH. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial. J Rheumatol 2009;36:2158-63. https://doi.org/10.3899/jrheum.090150
Cited by
- Infliximab : Peritoneal tuberculosis: case report vol.1436, pp.1, 2013, https://doi.org/10.1007/s40278-013-0930-y